89bio’s FGF21 Analog May Offer Fibrosis Benefit In Cirrhotic NASH Patients

 
• By Joseph Haas
  
Cirrhotic liver
89bio's pegozafermin shows fibrosis reduction in small subgroup of cirrhotic NASH patients • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D